Xtant Medical Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly20.9MTarget: 101000000 to 105000000
Gross Margin Quarterly5,730.0%Target: Expansion via core biologics focus
Non-GAAP Adjusted EBITDA Quarterly-1.6MTarget: Positive for full-year 2026
Watch Items
- Integration of Dilon Technologies' HEMOBLAST Bellows product and sales teamTrigger: Commercial execution and contribution to the raised FY26 revenue guidance of $101M-$105MAction: Monitor quarterly sales performance and commercial synergy realization from the 20-person sales team integration.
- Reimbursement changes and regulatory environment for skin-substitute and amniotic membrane linesTrigger: Cessation of high-margin Q-code license revenue impacting gross marginsAction: Track gross margin recovery as the company shifts focus to its core higher-margin biologics business.
Research as of 19 Jun 2026